Table 1.

Examples of the important clinical assays about γδ T-cell-based cancer immunotherapy.

Cancer Immunotherapy	Cancer Type	Results	Ref.
Treated with zoledronate+IL-2	Malignant melanomas	γδ T cells and the cancer's stage are negatively correlated, result in target cell lysis and death	120
Treated with zoledronate+IL-2	Hormone-refractory prostate cancer	Partial remission and stable disease, aggregate increases in γδ T cell numbers	66
Pretreated with pamidronate and zoledronate	MCF-7 breast tumor	Tumor cells were efficiently lysed, depended on the perforin-granzyme pathway.	126
Bone marrow grafts depleted of αβ T cells	Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML)	Have a significant improvement in disease-free survival, a post-BMT absolute increase in γδ T cells was significantly associated with αβ T-cell depletion.	127
Autologous γδ T cells infusion alone or with IL-2	Renal cell carcinoma (metastatic)	The maximum-tolerated dose and safety of γδ T cells is 8×109 cells.	128
Inoculation without cytokines	Non-small cell lung cancer	Progression is remarkablely inhibited.	134
In vitro proliferation of γδ T cells with pamidronate/IL-2	Non-Hodgkin lymphoma (relapsed and/or refractory) or multiple myeloma	Pamidronate/IL-2 was well tolerated, and no dose-limiting toxicity was observed.	138
Autologous γδ T cells	Colon carcinoma	Recognition and efficient killing of autologous and allogeneic CCCL (Colon Carcinoma Cell Lines)	139
Treated with zoledronic acid	Pancreatic carcinoma	Tumor cells treated with zoledronic acid are more vulnerable against γδ T cell attack.	140